A large dose of rosuvastatin combined with recombinant tissue plasminogen activator for patients with acute cerebral infarction

Abstract

Objective To investigate the clinical curative effect of a large dose of rosuvastatin combined with recombinant tissue plasminogen activator for patients with acute cerebral infarction. Methods 56 patients with acute cerebral infarction were randomly divided into a control group (28 cases) and an observation group (28 cases). All the patients were intravenously given thrombolytic therapy with recombinant tissue plasminogen activator. The control group was treated with rosuvastatin 10 mg/d after thrombolysis and the observation group 20 mg/d. 7 days were a treatment course; and both groups were treated 4 treatment courses. The differences in NIHSS score and BI score before and 7 and 30 d after treatment were compared between the two groups. Results There were no statistical differences in NIHSS score and BI score between the two groups before treatment (P>0.05). The NIHSS scores of the observation group 7 and 30 d after treatment were (5.1±2.7) and (4.3±2.5), which significantly were lower than those of the control group [(9.2±3.6) and (8.5±3.3)] (P<0.05). The BI scores of the observation group 7 and 30 d after treatment were (82.5±9.3) and (92.6±10.3), which were significantly lower than those of the control group [(70.8±8.9) and (81.7±9.8)] (P<0.05). Conclusions A large dose of rosuvastatin combined with recombinant tissue plasminogen activator for patients with acute cerebral infarction is effective and can effectively improve the patient's neurological function and the quality of the patients' daily life. Key words: Megadose; Rosuvastatin; Recombinant tissue plasminogen activator; Acute cerebral infarction